This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Andrew Ronald Joel Dunning Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ronald, A. Articles by Dunning, J. Search for Related Content PubMed PubMed Citation Articles by Ronald, A. Articles by Dunning, J. Related Collections Cardiac - pharmacology Education

Does perioperative thyroxine have a role during adult cardiac surgery?

^a Department of Cardiac Anaesthesia, Aberdeen Royal Infirmary, Aberdeen, UK
^b Department of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, UK

*Corresponding author. Tel./fax: +44-780-1548122.

E-mail address: joeldunning{at}doctors.org.uk (J. Dunning).

A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether the use of prophylactic perioperative thyroxine therapy during cardiopulmonary bypass in the euthyroid adult patient undergoing routine cardiac surgery can result in an improved cardiac output leading to better clinical outcomes. Altogether 86 papers were identified on Medline and 113 on Embase using the reported search. A further paper was identified by hand-searching of reference lists. Thirteen papers represented the best evidence on the topic. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses were tabulated. We conclude that it is clear that triiodothyronine levels decrease by 50% or more during cardiopulmonary bypass. However, there is conflicting evidence that prophylactic perioperative thyroxine/triiodothyronine therapy is a useful inotropic adjunct in adult patients undergoing routine cardiac surgery and whilst some studies report improved haemodynamic parameters in the immediate post-bypass period there is no evidence that its use influences postoperative morbidity, mortality or length of stay in the elective patient. It may, however, have a role as rescue therapy in supporting some high risk cases during weaning from CPB or bridging to LVAD or transplant.

Key Words: Cardiac surgery; Thyroxine; Triiodothyronine; Postoperative outcomes; Review; Evidence based medicine